ArQule (NASDAQ:ARQL) updated its FY 2019 earnings guidance on Wednesday. The company provided earnings per share guidance of $-0.37–0.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $-0.38. The company issued revenue guidance of $3-5 million, compared to the consensus revenue estimate of $4.25 million.
Several research firms recently issued reports on ARQL. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a report on Monday, July 29th. Oppenheimer set a $13.00 target price on ArQule and gave the stock a buy rating in a report on Thursday, July 11th. Royal Bank of Canada upped their target price on ArQule to $12.00 and gave the stock an outperform rating in a report on Wednesday, June 19th. B. Riley upped their target price on ArQule from $6.75 to $11.00 and gave the stock a buy rating in a report on Wednesday, May 29th. Finally, Roth Capital upped their target price on ArQule from $10.00 to $13.00 and gave the stock a buy rating in a report on Friday, June 14th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $12.17.
NASDAQ ARQL traded down $0.01 during trading on Friday, reaching $9.25. 1,080,273 shares of the company’s stock were exchanged, compared to its average volume of 1,597,202. The firm’s 50 day simple moving average is $10.56. The firm has a market capitalization of $1.01 billion, a PE ratio of -57.81 and a beta of 2.22. The company has a quick ratio of 6.45, a current ratio of 6.45 and a debt-to-equity ratio of 0.17. ArQule has a fifty-two week low of $2.23 and a fifty-two week high of $12.22.
ArQule (NASDAQ:ARQL) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $1.43 million. ArQule had a negative return on equity of 42.19% and a negative net margin of 349.34%. During the same quarter in the previous year, the business earned $0.05 earnings per share. On average, analysts forecast that ArQule will post -0.37 earnings per share for the current year.
In other ArQule news, Director Ran Nussbaum purchased 307,692 shares of the stock in a transaction on Thursday, June 27th. The shares were purchased at an average price of $9.75 per share, with a total value of $2,999,997.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 13.80% of the stock is owned by insiders.
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.
Recommended Story: Growth and Income Funds
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.